PBAC's latest decision on Atazanavir/cobicistat: Recommended with restriction (2015). Considered for Treatment of HIV-1 infection in adults, in combination with other antiretroviral agents. For treatment-naïve and treatment-experienced patients.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
HIV-1 infected adults, treatment-naïve and treatment-experienced, receiving atazanavir/cobicistat in combination with other antiretroviral agents.
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
RCT
Primary endpoint
ORR
Pivotal trial size
698 patients
Key trials
Study 511, Study 114, Study 105
Comparator
atazanavir plus ritonavir taken concomitantly
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.